Why is Capricor Therapeutics stock surging today?
Capricor Therapeutics (CAPR) stock rose 10% pre-market ahead of the FDA's November 22, 2026 decision on deramiocel, a therapy for Duchenne muscular dystrophy. Analysts JonesTrading and Oppenheimer upgraded CAPR, citing potential approval and peak sales of $2.3B. Despite market downturns, CAPR's surge is driven by FDA anticipation and clinical data.
How this was made
The 30-second read
Why it matters
The upcoming decision creates a short‑term speculative rally, but the binary outcome introduces significant downside risk.
Market read
CAPR's pre‑market surge reflects pure company‑specific catalyst (FDA decision) rather than macro trends, making it a high‑impact, short‑term trade idea.
What to watch
The three‑month PDUFA extension signals regulatory concerns that may weigh on approval odds.
Background
Capricor Therapeutics is developing an allogeneic cardiac‑derived cell therapy (deramiocel) for Duchenne muscular dystrophy. The FDA has set a Nov 22, 2026 PDUFA action date after a major amendment.
Ticker impact
Capricor Therapeutics stock surged ~10% in pre‑open trading ahead of the FDA's Nov 22 PDUFA decision on deramiocel.
upward pressure as investors accumulate ahead of the decision, with downside risk if the drug is rejected
Recent upgrade to Buy and a large put‑option build indicate high risk‑high reward positioning; the upcoming PDUFA date is the primary driver.
Market effects
Biotech sector may see heightened volatility around FDA decision dates.
Limited to U.S. biotech investors; broader market downtrend does not dampen CAPR's move.
Potential approval could open international markets for the therapy, but immediate impact is U.S.-centric.
Counterpoint
If the FDA rejects deramiocel, the stock could tumble 70% as highlighted by analysts.
Key entities
- companyCapricor Therapeutics
Biotech firm developing deramiocel for DMD.
- analyst_firmJonesTrading
Upgraded CAPR to Buy with a $25 price target.
- analyst_firmOppenheimer
Projected $50 target if deramiocel receives approval.



